Edda Dankmeyer
Edda Dankmeyer leads Sustainable Development Communications and explains how sustainable development can bea key differentiator for the company.
Search
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Supporting People with Diabetes and Related Conditions in the Time of COVID-19
Welcome to Innovation @ Boehringer Ingelheim
Welcome to Innovation @ Boehringer Ingelheim
Welcome to the Neuroscience Gallery | Boehringer Ingelheim US
Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.
Advocating for More Patient-Centered Mental Health Care
Advocating for More Patient-Centered Mental Health Care
Our Environment
Our Environment
Protein Degraders: Changing the Game in Cancer Drug Discovery
Protein Degraders: Changing the Game in Cancer Drug Discovery
Sustainable cattle production: Feeding the world while minimizing environmental effect
Sustainable cattle production: Feeding the world while minimizing environmental effect
Cardiologists at the Heart of Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Cardiologists at the Heart of Cardio-Renal-Metabolic Care
Transforming the Treatment of Lung Fibrosis through Lung Repair & Regeneration
Transforming the Treatment of Lung Fibrosis through Lung Repair & Regeneration
Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US
Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.
Focus on Alliance Management
Focus on Alliance Management
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
Welcome to Animal Health Partnering
Welcome to Animal Health Partnering
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office
Innovation in CardioMetabolic Disease Research
Innovation in CardioMetabolic Disease Research
MERIAL: RECOMBITEK® Oral Bordetella Vaccine | Boehringer Ingelheim US
MERIAL, now part of Boehringer Ingelheim, grows canine vaccine portfolio with the introduction of the RECOMBITEK® Oral Bordetella vaccine.
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Boehringer Ingelheim Announces the Launch of Centragard™ (eprinomectin and praziquantel transdermal solution), Innovative Internal Parasite Protection For Cats
Boehringer Ingelheim Medicine Post-Doctoral and Post-PharmD Fellowships
Boehringer Ingelheim Medicine Post-Doctoral and Post-PharmD Fellowships
Meet our scientist
Colleagues explain why they chose Boehringer Ingelheim
Management Rotation Program
Early Careers
Summer Internship Program
CAREER AREAS
Cookie Statement
Cookie Statement
Where to meet us | Animal Health Boehringer Ingelheim US
Find out where to meet the BD&L team virtually or in person at the next conference or event. Submit your opportunity to our BD&L team here.
Pre-Employment
Pre-Employment